Novartis broadens the reach of medicines to treat certain neglected and infectious diseases as well as non-communicable diseases around the world through strategic partnerships with multilateral and non-profit organizations. All our activities comply with the requirements set forth in the WHO Guidelines for Medicine Donations.
CancerPath to Care
Cancer Path to Care is a unique global initiative that connects people living with breast cancer, rare cancers such as chronic myeloid leukemia (CML), and rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH) to effective treatments, qualified healthcare professionals, and hands-on patient support.
The program is led by The Max Foundation in collaboration with Novartis, which provides donated medicines and financial support.
Through this partnership, we aim to have more than 30 000 patients actively receiving treatment each year across over 70 low- and middle-income countries (LMICs) through 2030. Eligible patients can receive Novartis treatments for breast cancer (Kisqali® and Femara®), as well as treatments from the CML portfolio (Glivec®, Tasigna®, and Scemblix®) and Fabhalta® for PNH.
Cancer Path to Care builds on a 25-year collaboration between The Max Foundation and Novartis, previously known as CML Path to Care. Originally launched in 2002 as the Glivec® International Patient Assistance Program, CML Path to Care provided medication at no cost to properly diagnosed patients in lower-income countries who lacked reimbursement options or were unable to afford treatment.
Leprosy
Since 2000, Novartis has helped fight leprosy by providing multidrug therapy (MDT) to patients worldwide through the World Health Organization, helping treat more than 8.3 million patients.
In 2026, we renewed our pledge to work to end leprosy by extending our donation of MDT medicines through 2025.
Learn more about our efforts to eliminate leprosy
Fascioliasis and paragonimiasis
Fascioliasis, commonly known as liver fluke, is caused by two species of parasitic flatworms or trematodes that mainly affect the liver. It belongs to the group of foodborne trematode infections. The WHO estimates that at least 2.4 million people are infected in more than 70 countries worldwide, with several million at risk. Triclabendazole is the only medicine recommended by WHO against fascioliasis and is part of the WHO Model List of Essential Medicines.
Since 2005, Novartis has provided Egaten® free of charge through the WHO to people with fascioliasis worldwide. Since the start of the program, Novartis has provided approximately 7.2 million tablets of Egaten, helping to treat around 2.4 million people with fascioliasis in more than 40 countries. In 2025, Novartis reaffirmed its commitment to the fight against fascioliasis, and additionally paragonimiasis, extending the agreement with the WHO until 2030.
Disaster relief efforts
When disaster strikes, we work with the international community and our local country organizations on the ground to provide support as quickly as possible to support those directly affected.
Our Disaster Relief Process enables us to make timely decisions and deliver aid in a sustainable and transparent manner based on the needs impacted communities. Depending on the situation, our activities include funds and/or matching gift programs.